Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

71.42USD
18 Jan 2019
Change (% chg)

$0.90 (+1.28%)
Prev Close
$70.52
Open
$70.91
Day's High
$71.74
Day's Low
$70.78
Volume
3,018,980
Avg. Vol
1,990,673
52-wk High
$74.91
52-wk Low
$55.59

Latest Key Developments (Source: Significant Developments)

Abbott To Acquire Cephea Valve Technologies, Inc.
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Abbott Laboratories ::ABBOTT TO ACQUIRE CEPHEA VALVE TECHNOLOGIES, INC..ABBOTT TO ACQUIRE CEPHEA VALVE TECHNOLOGIES, INC..ABBOTT LABORATORIES - FINANCIAL TERMS WERE NOT DISCLOSED.ABBOTT LABORATORIES - FINANCIAL TERMS WERE NOT DISCLOSED..ABBOTT LABORATORIES - EXERCISED OPTION TO BUY CEPHEA VALVE TECHNOLOGIES, A PRIVATELY HELD MEDICAL DEVICE CO.  Full Article

Abbott Raises Quarterly Dividend 14 Pct To $0.32/Share
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Abbott Laboratories ::RAISES QUARTERLY DIVIDEND 14%, INCREASING PAYOUTS FOR 47 STRAIGHT YEARS.INCREASES QUARTERLY DIVIDEND BY 14 PERCENT TO $0.32PER SHARE.  Full Article

Abbott Laboratories-Entered Into A Five Year Credit Agreement On Nov 30
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - ENTERED INTO A FIVE YEAR CREDIT AGREEMENT ON NOVEMBER 30.ABBOTT LABORATORIES - REVOLVING CREDIT AGREEMENT PROVIDES ABBOTT WITH THE ABILITY TO BORROW UP TO $5 BILLION ON AN UNSECURED BASIS.ABBOTT LABORATORIES - ANY BORROWINGS UNDER REVOLVING CREDIT AGREEMENT WILL MATURE AND BE PAYABLE ON FIFTH ANNIVERSARY OF EFFECTIVE DATE.ABBOTT LABORATORIES - ABBOTT TERMINATED ALL COMMITMENTS OUTSTANDING UNDER FIVE YEAR CREDIT AGREEMENT, DATED JULY 10, 2014 WITH BANK OF AMERICA.  Full Article

NY A.G. Underwood Announces Settlement With Abbott Labs
Friday, 9 Nov 2018 

Nov 9 (Reuters) - New York Attorney General Barbara Underwood::SETTLEMENT RESOLVING INVESTIGATION INTO ABBOTT LABORATORIES OVER "MISLEADING" MARKETING SURVEYS COMPANY SENT.SAYS SETTLEMENT REQUIRES ABBOTT TO ACCURATELY DISCLOSE PURPOSE FOR WHICH SURVEY INFORMATION IS SOUGHT.SETTLEMENT ALSO REQUIRES ABBOTT TO PAY $50,000 IN COSTS.  Full Article

Abbott's Heartmate 3 Heart Pump Now FDA Approved For Advanced Heart Failure Patients Not Eligible For Heart Transplant
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Abbott Laboratories ::ABBOTT'S HEARTMATE 3 HEART PUMP NOW FDA APPROVED FOR ADVANCED HEART FAILURE PATIENTS NOT ELIGIBLE FOR A HEART TRANSPLANT.  Full Article

Abbott Labs Sees FY 2018 Organic Sales Growth Of About 7 Pct
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - Abbott Laboratories ::SEES FY 2018 ORGANIC SALES GROWTH OF ABOUT 7 PERCENT - CONF. CALL.SEES Q4 ORGANIC SALES GROWTH OF MID-TO-HIGH SINGLE DIGITS.  Full Article

Abbott Laboratories Reports Q3 Adjusted EPS $0.75 From Continuing Operations
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - Abbott Laboratories ::ABBOTT REPORTS THIRD-QUARTER 2018 RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.75 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q3 GAAP EARNINGS PER SHARE $0.31 FROM CONTINUING OPERATIONS.Q3 EARNINGS PER SHARE VIEW $0.75 -- THOMSON REUTERS I/B/E/S.SEES Q4 ADJUSTED EARNINGS PER SHARE $0.80 TO $0.82 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $2.87 TO $2.89 FROM CONTINUING OPERATIONS.SEES Q4 2018 GAAP EARNINGS PER SHARE $0.39 TO $0.41 FROM CONTINUING OPERATIONS.THIRD-QUARTER REPORTED SALES GROWTH OF 12.1 PERCENT; ORGANIC SALES GROWTH OF 7.8 PERCENT.THIRD-QUARTER WORLDWIDE SALES OF $7.7 BILLION.QTRLY TOTAL PEDIATRIC SALES $1,039 MILLION VERSUS $975 MILLION REPORTED LAST YEAR.QTRLY TOTAL NUTRITION SALES $1,838 MILLION VERSUS $1,768 MILLION REPORTED LAST YEAR.QTRLY TOTAL DIAGNOSTICS SALES $1,824 MILLION VERSUS $1,279 MILLION REPORTED LAST YEAR."IN SPITE OF INCREASING CURRENCY HEADWINDS, WE'RE WELL-POSITIONED TO ACHIEVE UPPER END OF OUR INITIAL FULL-YEAR GUIDANCE".SEES FULL-YEAR 2018 DILUTED EPS GUIDANCE RANGE FROM CONTINUING OPERATIONS ON A GAAP BASIS $1.33 TO $1.35.Q3 REVENUE VIEW $7.65 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $2.89 -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $0.82 -- THOMSON REUTERS I/B/E/S.NARROWED ITS FULL-YEAR 2018 DILUTED EPS GUIDANCE RANGE FROM CONTINUING OPERATIONS ON A GAAP BASIS TO $1.33 TO $1.35.  Full Article

Abbott's Freestyle Libre 2 Secures CE Mark For Use In Europe
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Abbott Laboratories ::ABBOTT′S FREESTYLE® LIBRE 2, WITH OPTIONAL REAL-TIME ALARMS, SECURES CE MARK FOR USE IN EUROPE.  Full Article

Abbott Receives CE Mark For First Troponin Test To Help Predict The Chance Of Heart Attack
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Abbott Laboratories ::ABBOTT RECEIVES CE MARK FOR FIRST TROPONIN TEST TO HELP PREDICT THE CHANCE OF HEART ATTACK IN APPARENTLY HEALTHY ADULTS POTENTIALLY MONTHS TO YEARS IN ADVANCE.  Full Article

One-Year Results From Real-World Study Showed Abbott's Portico Transcatheter Aortic Valve Safely And Successfully Reduced Severe Aortic Stenosis
Tuesday, 25 Sep 2018 

Sept 25 (Reuters) - Abbott Laboratories ::ONE-YEAR RESULTS FROM REAL-WORLD STUDY SHOWED ABBOTT'S PORTICO TRANSCATHETER AORTIC VALVE SAFELY AND SUCCESSFULLY REDUCED SEVERE AORTIC STENOSIS.ABBOTT-AT 1 YEAR, IMPLANTATION WITH PORTICO VALVE WAS SAFE,ASSOCIATED WITH LOW RATES OF STROKE, DEATH,LEAKS BETWEEN PATIENTS' NATURAL HEART TISSUE & PORTICO VALVE.  Full Article

REFILE-Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Dec 17 Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial.